Citius Oncology, Inc.CTOR
Oncology15 cited findings · profile updated 2026-08-20
0.75 USDnot live — refreshed daily
About Citius Oncology, Inc.
Citius Oncology, Inc. (CTOR) is focused on oncology. The company's drug, LYMPHIR, received FDA approval in the United States in December 2025. As of July 2026, 383 vials of LYMPHIR were ordered, with 31% of LYMPHIR vials ordered sequentially. LYMPHIR has been prescribed and ordered by 44 institutions, and there has been an 80% increase in new ordering institutions. The initial CTCL market for LYMPHIR is 400 million.
In a Phase 1 study of LYMPHIR with pembrolizumab, the median progression-free survival was 20.5 months. The objective response rate (ORR) for LYMPHIR with pembrolizumab was reported as 24% and 33%. LYMPHIR is also being studied prior to CAR-T therapy in a Phase 1 study. In this setting, the objective response rate (ORR) for LYMPHIR prior to CAR-T therapy was 86%, with a complete response (CR) of 57% and a partial response (PR) of 29%. No dose-limiting toxicities were observed for LYMPHIR prior to CAR-T therapy.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| LYMPHIR FDA approval date | December 2025 | CITIUS ONCOLOGY, INC. — SEC 8-K (2026-08-14), p.p.3 |
| median progression-free survival | 20.5 months for LYMPHIR with pembrolizumab | CITIUS ONCOLOGY, INC. — SEC 8-K (2026-08-14), p.p.2 |
| objective response rate (ORR) | 86% for LYMPHIR prior to CAR-T therapy | CITIUS ONCOLOGY, INC. — SEC 8-K (2026-08-14), p.p.2 |
| complete response (CR) | 57% for LYMPHIR prior to CAR-T therapy | CITIUS ONCOLOGY, INC. — SEC 8-K (2026-08-14), p.p.2 |
| dose-limiting toxicities | no for LYMPHIR prior to CAR-T therapy | CITIUS ONCOLOGY, INC. — SEC 8-K (2026-08-14), p.p.2 |
| Initial CTCL market for LYMPHIR | 400 million | CITIUS ONCOLOGY, INC. — SEC 8-K (2026-08-14), p.p.4 |
Key projects
- LYMPHIR — US
LYMPHIR received FDA approval in the United States in December 2025.
- LYMPHIR with pembrolizumab
In a Phase 1 study, LYMPHIR with pembrolizumab demonstrated a median progression-free survival of 20.5 months.
- LYMPHIR prior to CAR-T therapy
In a Phase 1 study, LYMPHIR prior to CAR-T therapy showed an objective response rate (ORR) of 86%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →